Nagesh K. Mahanthappa, PhD, MBA
CEO & President

Dr. Mahanthappa is a biotechnology entrepreneur with over 20 years of industry experience in roles spanning discovery research through early clinical development, as well as operations and strategy. Prior to Scholar Rock®, Dr. Mahanthappa was a founding employee and VP, Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene Corporation in 2012). Avila discovered and developed novel covalent drugs for the treatment of cancer, autoimmune, and viral diseases. He was previously a founding employee of Alnylam Pharmaceuticals, the first biotech established to discover RNA interference therapeutics and rose to VP, Scientific & Strategic Development. Earlier professional roles include business development at Vertex Pharmaceuticals, and discovery research at Ontogeny (now Curis, Inc.) and Cambridge NeuroScience. He was also a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now Alere, Inc.) in 2010. Dr. Mahanthappa received his Ph.D. in Neurobiology from the California Institute of Technology, and post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. He received his MBA from the F.W. Olin Graduate School of Management at Babson College.

Elan Z. Ezickson
Chief Operating Officer & Head of Corporate Development

Mr. Ezickson has more than 20 years of experience in building leading companies in the biotechnology industry. Prior to Scholar Rock®, Mr. Ezickson served as Executive Vice President and Chief Operating Officer at AVEO Pharmaceuticals where he built and oversaw commercial operations, technical operations, medical affairs, corporate development, program management and legal affairs. While at AVEO, Mr. Ezickson led the formation of numerous collaborations around AVEO’s clinical development and translational research programs with strategic partners including Astellas, Janssen Biotech, OSI Pharmaceuticals, Merck, Schering-Plough and Biogen Idec, raising more than $350 million in proceeds from these collaborations. AVEO’s co-development/co-commercialization alliance with Astellas Pharmaceuticals was the recipient of the Scrip 2011 Licensing Deal of the Year Award. Prior to joining AVEO in 2003, he spent 9 years in leadership roles at Biogen that included President of Biogen Canada, Program Executive and Associate General Counsel. Mr. Ezickson holds a B.A. in Political Science from Yale University and a J.D. from the Columbia University School of Law.

Yung H. Chyung, MD
Chief Medical Officer

Dr. Chyung is a leader in drug development and medical affairs with a track record of driving forward innovative medicines. Prior to joining Scholar Rock, Dr. Chyung was Vice President of Medical Research at Dyax Corp., where he was responsible for clinical trials, translational medicine and medical affairs. At Dyax, he successfully led the clinical program for DX-2930 (a monoclonal antibody being investigated for the prevention of hereditary angioedema attacks) to proof of concept, resulting in FDA Breakthrough Therapy designation and the opportunity to proceed directly from Phase 1b to a pivotal Phase 3 trial. He also was the medical lead for Kalbitor® (approved in the U.S. for treatment of acute attacks of hereditary angioedema) as well as other product candidates in development. Prior to Dyax, Dr. Chyung worked at Genzyme Corporation where he was responsible for medical affairs efforts globally for multiple approved products for rare genetic diseases. Dr. Chyung earned his MD from Harvard Medical School and completed his internal medicine residency and allergy and immunology fellowship at Massachusetts General Hospital. He holds an AB in Biochemical Sciences from Harvard College.

Alan J. Buckler, PhD
Chief Scientific Officer

Dr. Buckler is a seasoned drug discovery leader with over 25 years of research experience in industry and academia, culminating most recently as Vice President, Cell and Protein Sciences, at Biogen. Dr. Buckler’s 20-year career in the biotechnology and pharmaceutical industries has spanned roles of increasing responsibility in early-stage private companies and established public corporations. After nearly a decade of leading a variety of drug discovery programs at the Novartis Institutes of Biomedical Research, he most recently served as Vice President in Drug Discovery at Biogen. Prior to joining the private sector, Dr. Buckler served on the Neurology faculty of Massachusetts General Hospital and Harvard Medical School for 6 years. Dr. Buckler received his AB from the University of Chicago, PhD in Microbiology from the Boston University School of Medicine, and completed his post-doctoral training at the Massachusetts Institute of Technology.

Gregory J. Carven, PhD
Vice President, Antibody Discovery & Protein Sciences

Dr. Carven is an acknowledged leader in the discovery and development of antibody therapeutics. A particular highlight of his more than 15 years of antibody discovery experience was his leadership of the discovery and preclinical development of Keytruda® (pembrolizumab; MK-3475; anti-PD-1) from its invention through to IND filing. Dr. Carven was recognized for his invention of the lifesaving cancer medicine, Keytruda®, with his receipt of “Inventor of the Year” in 2016 by the Intellectual Property Owners Education Foundation. Most recently, he was head of hybridoma research within Pfizer’s Global Biotherapeutics Technologies division and was responsible for discovery and engineering of antibodies and antibody binding domains for a wide variety of therapeutic areas. Prior to joining Pfizer, Dr. Carven held positions of increasing responsibility at Merck Research Laboratories (formerly Schering Plough Research Institute and Organon Biosciences), and was a scientist at Phylogix, Inc. Dr. Carven received his PhD in Biological Chemistry from the Massachusetts Institute of Technology, and continued his research on the characterization of conformational changes in class II MHC molecules using conformation-specific monoclonal antibodies at the University of Massachusetts Medical School.

Heather Faulds
Vice President, Regulatory Affairs

Ms. Faulds has over 15 years of regulatory experience at innovative biotechnology companies across all stages of development, from first-in-human studies to product approvals and product label expansions. She most recently served as Senior Director of Regulatory Affairs at Biogen, where she designed and implemented innovative regulatory strategies that expedited the development path and approval for multiple products, including Spinraza® (nusinersen), an orphan product for the treatment of Spinal Muscular Atrophy (SMA), which was approved by FDA in an unprecedented 90 days and received an FDA Priority Review Voucher. In addition, Ms. Faulds led the regulatory activities for programs in Alzheimer’s Disease and Multiple Sclerosis. Prior to working at Biogen, Ms. Faulds was Manager, Regulatory Affairs and CMC Operations at Oxigene, Inc. Ms. Faulds earned her masters degree in Drug Regulatory Affairs and Health Policy at the Massachusetts College of Pharmacy. She also holds a BS in Biology from the University of Albany.

“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2018 Scholar Rock All Rights Reserved.
Back to Top

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel